<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="23" ids="18059">Lipid</z:chebi> accumulation in nonadipose tissues is closely related to the development of type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> subjects </plain></SENT>
<SENT sid="1" pm="."><plain>We examined the potential preventive effect of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma stimulation on the development of <z:mp ids='MP_0002055'>diabetes</z:mp> in <z:mp ids='MP_0001261'>obese</z:mp> <z:mp ids='MP_0002055'>diabetes</z:mp>-prone OLETF rats </plain></SENT>
<SENT sid="2" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> administration of a PPAR-alpha <z:chebi fb="4" ids="48705">agonist</z:chebi> (0.5% [wt/wt] <z:chebi fb="0" ids="5001">fenofibrate</z:chebi>) or a PPAR-gamma <z:chebi fb="4" ids="48705">agonist</z:chebi> (3 mg x kg(-1) x day(-1) <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi>) completely prevented the development of <z:hpo ids='HP_0003076'>glycosuria</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>Pancreatic islets from untreated OLETF rats underwent sequential <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> and <z:mpath ids='MPATH_127'>atrophy</z:mpath>, which was completely prevented by <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> treatment </plain></SENT>
<SENT sid="4" pm="."><plain>In contrast, <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment did not affect islet <z:mpath ids='MPATH_159'>hypertrophy</z:mpath> at earlier stages but prevented beta-cell <z:mpath ids='MPATH_127'>atrophy</z:mpath> at later stages </plain></SENT>
<SENT sid="5" pm="."><plain><z:chebi fb="0" ids="5001">Fenofibrate</z:chebi> treatment <z:hpo ids='HP_0004325'>decreased body weight</z:hpo> and visceral fat, whereas <z:chebi fb="0" ids="50122">rosiglitazone</z:chebi> treatment <z:hpo ids='HP_0004324'>increased body weight</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Despite the opposite effects on <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, both drugs were equally effective in improving insulin actions in skeletal muscle </plain></SENT>
<SENT sid="7" pm="."><plain>Furthermore, both drugs significantly decreased the <z:chebi fb="0" ids="17855">triglyceride</z:chebi> content in the soleus muscle and pancreatic islets </plain></SENT>
<SENT sid="8" pm="."><plain>The present study demonstrates that the PPAR-alpha <z:chebi fb="4" ids="48705">agonist</z:chebi> <z:chebi fb="0" ids="5001">fenofibrate</z:chebi> prevents the development of <z:mp ids='MP_0002055'>diabetes</z:mp> in OLETF rats by reducing <z:e sem="disease" ids="C0028754" disease_type="Disease or Syndrome" abbrv="">adiposity</z:e>, improving peripheral insulin action, and exerting beneficial effects on pancreatic beta-cells </plain></SENT>
</text></document>